Measles: Not just another viral exanthem

Lancet

Volumn 361, Issue 9359, 2003, Pages 763-773

  Duke, Trevor ^a   Mgone, Charles S ^b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; VIRUS VACCINE;

ANTIBIOTIC THERAPY; BACTERIAL SUPERINFECTION; CHILDHOOD MORTALITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE DURATION; DISEASE PREDISPOSITION; ECONOMIC ASPECT; ENDEMIC DISEASE; EPIDEMIC; FATALITY; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; MEASLES; MEASLES VIRUS; MORTALITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RASH; RISK FACTOR; SURVIVAL RATE; TUBERCULOSIS; VACCINATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 0037333202     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12661-X     Document Type: Conference Paper

References (142)

1. Public health expenditure per capita: World Health Report 2000. 2000;192-195 World Health Organization, Geneva.
2. WHO. Vaccines and biologicals: WHO vaccine-preventable diseases - 2002 global summary. http://www.who.int/vaccines-documents/GlobalSummary/GlobalSummary.pdf (accessed Jan 21, 2003).
3. Kingsbury D.W., Bratt M.A., Choppin P.W., et al. Paramyxoviradae. Intervirology. 10:1978;137-152.
4. Wild T.F., Malvoisin E., Buckland R. Measles virus: both the hemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol. 72:1991;439-442.
5. Nussbaum O., Broder C.C., Moss B., Bar-Lev Stern L., Rozenblatt S., Berger E.A. Functional and structural interaction between measles virus hemagglutinin and CD46. J Virol. 69:1995;3341-3349.
6. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 406:2000;893-897.
7. Erlenhoefer C., Wurzer W.J., Loffler S., Schneider-Schaulies S., ter-Meulen V., Schneider-Schaulies J. CD150 (SLAM) is the receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition. J Virol. 75:2002;4499-4505.
8. Naniche D., Varion-Krishnan G., Cervoni F., et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 67:1993;6025-6032.
9. Döring R.E., Marcil A., Chopra A., Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 75:1993;295-305.
10. Expanded Programme on Immunization (EPI): standardization of the nomenclature for describing the genetic characteristics of wild-type measles virus. Wkly Epidemiol Rec. 73:1998;265-269.
11. Nomenclature for describing the genetic characteristics of the wild-type measles virus (update), part 1. Wkly Epidemiol Rec. 76:2001;242-247.
12. Nomenclature for describing the genetic characteristics of the wild-type measles virus (update), part 2. Wkly Epidemiol Rec. 76:2001;249-251.
13. Bellini W.J., Rota P.A. Genetic diversity of wild-type measles: implications for global elimination programs. Emerg Infect Dis. 4:1998;29-35.
14. Nahamias A.J., Griffith D., Salisbury D., Yoshida K. Thymic lymphoplasia with lymphopenia, plasma cells and normal immunoglobulins. JAMA. 201:1967;729-734.
15. Griffin D.E. Measles virus. Fields B.N., Knipe D.M., Howley P.M., et al. Fields virology. 1990;1401-1441 Williams and Wilkins, New York.
16. Kaplan L.J., Daum R.S., Smaron M., McCarthy C.A. Severe measles in immunocompromised patients. JAMA. 267:1992;1237-1241.
17. Pederson I.R., Modhorst C.H., Ewald T. Long term antibody response after measles vaccine in an isolated Arctic society in Greenland. Vaccine. 4:1986;173-178.
18. Panua P. Observations made during the epidemic of measles on the Faroe Islands in the year 1846. Med Classics. 11:1992;525-529.
19. Black F.L., Rosen L. Patterns of measles antibodies in residents of Tahiti and their stability in the absence of re-exposure. J Immunol. 88:1962;725-731.
20. Van Binnendiijk R.S., Poelen M.C.M., Kuijpers K.C., Osterhaus A.D., Uytdehaag F.G. The predominance of CD8+ T cells after infection with measles virus suggests a role of CD8+ class 1 MHC-restricted cytotoxic T lymphocytes (CTL) in recovery from measles. J Immunol. 144:1990;2394-2399.
21. Wu V.H., McFarland H., Mayo K., Hanger L., Griffin D.E., Dhib-Jalbut S. Measles virus-specific cellular immunity in patients with vaccine failure. J Clin Microbiol. 31:1993;118-122.
22. Graves M., Griffin D.E., Johnson R.T., Hirsch R.L., de Soriano I.L. Development of antibody to measles virus polypeptides during complicated and uncomplicated measles infections. J Virol. 38:1984;224-230.
23. Liebert U.G. Measles virus infection of the central nervous system. Intervirology. 40:2002;175-184.
24. Samb B., Aaby P., Whittle H. Serological status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J. 14:1995;203-209.
25. Benett J., Whittle H., Samb B., Cisse B., Simondon F., Aaby P. Serocoversion in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal. Int J Epidemiol. 28:1999;146-151.
26. Johnson RT, Griffin DE. Virus-induced autoimmune demyelinating disease of the CNS. In: Norkins AL, Oldstone MBA, eds. Concepts in viral pathogenesis. Berlin: Springer, 20 AD:203-09.
27. Johnson R.T., Griffin D.E., Hirsch R.L. Measles encephalitis: clinical and immunologic studies. N Engl J Med. 310:1964;137-141.
28. Gendelman H., Wolinsky J.S., Johnson R.T., Pressmann R.T., Pezeshpour G.H. Measles infection: lack of evidence of viral invasion in the central nervous system and quantitative study of the nature of demyelination. Ann Neurol. 15:1984;353-360.
29. Roos R.P., Graves W.C., Wollmann R.L., Chilote R.R., Nixon J. Immunologic and virologic studies of measles inclusion body encephalitis in an immunocompromised host: the relationship to subacute sclerosing panencephalitis. Neurology. 31:1981;263-270.
30. Mustafa M.W., Weitman S.D., Winick N.J., Belini W.J., Timmons C.F., Siegel J.D. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis. 16:1993;654-660.
31. Miki K., Komase K., Mgone C.S., et al. Molecular analysis of measles virus genome derived from SSPE and acute measles in patients in Papua, New Guinea. J Med Virol. 68:2002;105-112.
32. Saha V., John T.J., Mukundan P., et al. High incidence of subacute schlerosing panencephalitis in south India. Epidemiol Infect. 104:1990;151-156.
33. Cernescu C., Milea S., Berbescu C., Pastia M., Popescu L. SSPE: some clues to pathogenesis from epidemiological data. Virologie. 39:1998;247-256.
34. Kipps A., Makenzie D.J., McDonald R. Register of cases of subacute schlerosing panencephalitis in Southern Africa. S Afr Med J. 52:1977;1038-1041.
35. Anlar B., Kose G., Gurer Y., Altunbasak S., Haspolat S., Okan M. Changing epidemiological features of subacute sclerosing panencephalitis. Infection. 29:2001;192-195.
36. Schneider-Schaulies S, ter Meulen V. Measles virus and immunomodulation: molecular bases and perspectives. Exp Rev Mol Med2002; http://www.expertreviews.org/02004696h.htm (accessed Jan 15, 2003).
37. Karp C.L. Measles: immunosuppression, interleukin-12, and complement receptors. Immunol Rev. 168:1999;91-101.
38. Esolen L.M., Ward B.J., Moench T.R., Griffin D.E. Infection of monocytes during measles. J Infect Dis. 168:1993;47-52.
39. Griffin D.E., Johnson T.R., Tamashiro V.G., et al. In vitro studies of the role of monocytes in the immunosuppression associated with natural measles virus infection. Clin Immunol Immunopathol. 45:1987;375-383.
40. Engelking O., Fedorov L.M., Lilischkis R., ter Meulen V. Measles virus-induced immunosuppression in vitro is associated with deregulation of G1cell cycle control proteins. J Gen Virol. 80:1999;1599-1608.
41. Garenne M., Aaby P. Pattern of exposure and measles mortality in Senegal. J Infect Dis. 161:1990;1088-1094.
42. Katz M. Clinical spectrum of measles. Curr Top Microbiol Immunol. 191:1995;1-12.
43. Flick J.A. Does measles really predispose to tuberculosis? Am Rev Respir Dis. 114:1976;257-265.
44. Gocmen A., Cengizlier R., Ozcelik U., Kiper N., Senuyar R. Childhood tuberculosis: a report of 2205 cases. Turk J Pediatr. 39:1997;149-158.
45. Gurkan F., Bosnak M., Dikici B., et al. Miliary tuberculosis in children: a clinical review. Scand J Infect Dis. 30:1998;359-362.
46. Maniar B.M. Cavitating pulmonary tuberculosis below age of 2 years. Indian Pediatr. 31:1994;181-190.
47. Rahajoe N.N. Miliary tuberculosis in children: a clinical review. Paediatr Indones. 30:1990;233-240.
48. Cundall D.B. The diagnosis of pulmonary tuberculosis in malnourished Kenyan children. Ann Trop Paediatr. 6:1986;249-255.
49. Nemir R.L., O'Hare D. Tuberculosis in children 10 years of age and younger: three decades of experience during the chemotherapeutic era. Pediatr. 88:1991;236-241.
50. Raote G.J., Bhave S.Y. Clinical profile of measles: a prospective study of 150 hospital based children. Indian Pediatr. 29:1992;45-48.
51. Leoning W.E., Coovadia H.M. Age-specific occurrence rates of measles in urban, peri-urban, and rural environments: implications for time of vaccination. Lancet. 2:1983;324-326.
52. de Francisco A., Fauveau V., Sarder A.M., Chowdhury H.R., Chakraborty J., Yunus M.D. Measles in rural Bangladesh: issues of validation and age distribution. Int J Epidemiol. 23:1994;393-399.
53. Mgone J., Mgone C., Duke T., Frank D., Yeka W. Control measures and the outcome of the measles epidemic of in the Eastern Highlands Province. PNG Med J2000. 43:1999;90-97.
54. Quiambao B.P., Gatchalian S.R., Halonen P., et al. Coinfection is common in measles associated pneumonia. Pediatr Infect Dis J. 17:1998;89-93.
55. Coakley K.J., Coakley C.A., Spooner V., Smith T.A., Javati A., Kajoi M. A review of measles admissions and deaths in the paediatric ward of Goroka Base Hospital in 1989. PNG Med J. 34:1991;6-12.
56. Aaby P., Bukh J., Hoff G., et al. High measles mortality in infancy related to intensity of exposure. J Pediatr. 109:1986;40-44.
57. Moss W.J., Monze M., Ryon J.J., Quinn T.C., Griffin D.E., Cutts F. Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis. 35:2002;189-196.
58. Perry R., Mmiro F., Ndugwa C., Semba R.D. Measles infection in HIV-infected African infants. Ann N Y Acad Sci. 918:2000;377-380.
59. Schnorr J.J., Cutts F.T., Wheeler J.G., et al. Immune modulation after measles vaccination of 6-9 months old Bangladeshi infants. Vaccine. 19:2001;1503-1510.
60. Metintas S., Akgum Y., Arslantas D., Kalyoncu C., Ucar B. Decay of maternally derived measles antibodies in central Turkey. Public Health. 116:2002;50-54.
61. Cutts F.T., Nyandu B., Markowitz L.E., et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month old infants, in Kinshasa, Zaire. Vaccine. 12:2002;1311-1316.
62. Cutts F.T., Grabowsky M., Markowitz L.E. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals. 23:1995;95-106.
63. Expanded Programme on Immunization. Global advisory group. Wkly Epidemiol Rec1990; 65: 5-11.
64. Expanded program on immunization. Safety of high titre measles vaccine. Wkly Epidemiol Rec1992; 67: 357-61.
65. Kaschula R.O.C., Druker J., Kipps A. Late morphologic consequences of measles: a lethal and debilitating lung disease among the poor. Rev Infect Dis. 5:1983;395-404.
66. Anon. Standard treatment for common illnesses of children in Papua New Guinea: a manual for nurses, health extension officers and doctors. Port Moresby: PNG Department of Health, 2000.
67. Semba R.D., Munasir Z., Beeler J., et al. Reduced seroconversion to measles in infants given vitamin A with measles vaccination. Lancet. 345:1995;1330-1332.
68. Benn C.S., Aaby P., Bale C., et al. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. Lancet. 350:1997;101-105.
69. Semba R.D., Akib A., Beeler J., et al. Effect of vitamin A supplementation on measles vaccination in nine-month-old infants. Public Health. 111:1997;245-247.
70. Bahl R., Kumar R., Bhandari N., Kant S., Srivastava R., Bhan M.K. Vitamin A administered with measles vaccine to nine-month-old infants does not reduce vaccine immunogenicity. J Nutr. 129:1999;1569-1573.
71. Mulholland K. Measles and pertussis in developing countries with good vaccination coverage. Lancet. 345:1995;305-307.
72. Coetzee N., Hussey G.D., Visser G., Barron P., Keen A. The 1992 measles epidemic in Cape Town: a changing epidemiological pattern. S Afr Med J. 84:1994;145-149.
73. Paunio M., Hedman K., Davidkin I., et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect. 124:2000;263-271.
74. Hirose M., Hidaka Y., Miyazaki C., Ueda K., Yoshikawa H. Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination. Scand J Infect Dis. 29:1997;187-190.
75. Mathias R.G., Meekison W.G., Arcand T.A., Schechter M.T. The role of secondary vaccine failures in measles outbreaks. Am J Public Health. 79:1989;475-478.
76. Panagiotopoulos T., Antoniadou I., Valassi-Adam E. Increase in congenital rubella occurrence after immunization in Greece: retrospective survey and systematic review. BMJ. 319:1999;1462-1467.
77. Plotkin S.A. Rubella eradication. Vaccine. 19:2001;3311-3319.
78. Wakefield A.J., Murch S.H., Anthony A., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 351:1998;637-641.
79. Nicoll A., Elliman D., Ross E. MMR vaccination and autism 1998. BMJ. 316:1998;715-716.
80. Taylor B., Miller E., Farrington C.P., et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet. 353:1999;2026-2029.
81. Kaye J.A., del Mar Melero-Montes M., Jick H. Mumps, measles and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ. 322:2001;460-463.
82. Peltola H., Patja A., Leinikki P., Valle M., Davidkin I., Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet. 351:1998;1327-1328.
83. Fombonne E., Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatr. 109:2001;991.
84. Afzal M.A., Minor P.D., Schild G.C. Clinical safety issues of measles, mumps and rubella vaccines. Bull World Health Organ. 78:2000;199-204.
85. Immunization safety review: measles-mumps-rubella vaccine and autism. 2001;National Academy Press, Washington.
86. Gove S. Integrated management of childhood illness by outpatient health workers: technical basis and overview: the WHO working group on guildelines for integrated management of the sick child. Bull World Health Organ. 75:(suppl):1997;7-24.
87. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries. 2000;WHO, Geneva.
88. Barclay A.J.G., Foster A., Sommer A. Vitamin A supplements and mortality related to measles: a randomised clinical trial. BMJ. 294:1987;296.
89. Hussey G.D., Klein M. A randomised controlled trial of Vitamin A in children with severe measles. N Engl J Med. 323:1992;160-164.
90. Ellison J.B. Pneumonia in measles. Arch Dis Child. 6:1931;37-51.
91. Duke T., Michael A., Mgone J., Frank D., Wal T., Sehuko R. Etiology of child mortality in Goroka, Papua New Guinea: a prospective two-year study. Bull World Health Organ. 80:2002;16-25.
92. Shann F. Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence. BMJ. 314:1997;334-336.
93. Rosales F.J., Kjolhede C., Goodman S. Efficacy of a single oral dose of 200,000 IU of oil-soluble vitamin A in measles associated morbidity. Am J Epidemiol. 143:2002;413-422.
94. Duke T., Poka H., Dale F., Michael A., Mgone J., Wal T. Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial. Lancet. 359:2002;474-480.
95. Wesley A.G., Sutton J.B., Widrich A.J. The aetiology of pneumonia associated with measles in Bantu children. S Afr Med J. 45:1971;1402-1404.
96. Olsen R.W., Hodges G.R. Measles pneumonia: bacterial superinfection as a complicating factor. JAMA. 232:2002;363-365.
97. Dover A.S., Escobar J.A., Duenas A.L., Leal E.C. Pneumonia associated with measles. JAMA. 234:2002;612-614.
98. Gremillion D.H., Crawford G.E. Measles pneumonia in young adults: an analysis of 106 cases. Am J Med. 71:1981;539-542.
99. Morton R., Mee J. Measles pneumonia: lung puncture findings in 56 cases related to chest X-ray changes and clinical features. Ann Trop Paediatr. 6:1986;41-45.
100. Shann F. Bacterial pneumonia: commoner than perceived. Lancet. 357:2001;2070-2072.
101. Kipps A., Kaschula R.O.C. Virus pneumonia following measles: a virological and histological study of autopsy material. S Afr Med J. 50:1976;1083-1088.
102. Kaschula R.O.C., Druker J., Kipps A. Late morphological consequences of measles: a lethal and debilitating lung disease among the poor. Rev Infect Dis. 5:1983;395-404.
103. Warner J.O., Marshall W.C. Crippling lung disease after measles and adenovirus infection. Br J Chest Med. 70:1976;89-94.
104. Sly P.D., Soto-Quiros M.E., Landau L.I., Hudson I., Newton-John H. Factors predisposing to abnormal pulmonary function after adenovirus type 7 pneumonia. Arch Dis Child. 59:1984;935-939.
105. Permar S.R., Moss W.J., Ryon J.J., et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detection by reverse transcriptase-polymerase chain reaction. J Infect Dis. 183:2001;532-538.
106. Oshitani H., Suzuki M.E., Mpabalwani M.E., Mizuta K., Numazaki Y. Measles case fatality by sex, vaccination status, and HIV-1 antibody in Zambian children. Lancet. 348:1996;415.
107. Sension M.G., Quinn T.C., Markowitz L.E., et al. Measles in hospitalized African children with human immunodeficiency virus. Am J Dis Child. 142:1988;1271-1272.
108. Arpadi S.M., Markowitz L.E., Baughman A.L., et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatr. 97:1996;653-657.
109. D'Souza R.M., D'Souza R. Vitamin A for treating measles in children (Cochrane Review). The Cochrane Library. 2001;Update Software, Oxford. issue 1.
110. Shann F., D'Souza R.M., D'Souza R. Antibiotics for preventing pneumonia in children with measles (Cochrane Review). The Cochrane Library. 2002;Update Software, Oxford. issue 1.
111. Karelitz S., Chang C., Matthews Z.E. the prophylaxis and treatment of bacterial complications of measles with bezethacil and aqueous procaine penicillin G. J Paediatr. 44:1954;357-363.
112. Prasad R., Mathyr G.P., Trehan O.P., Mehrota M.L., Dayal R.S. A Clinical and radiological study of measles. Indian Paedtr. 4:1967;243-250.
113. Anderson T. Sulphanilamide in the treatment of measles. BMJ. 1:1939;716-718.
114. Hogarth J.C. Para-benzylaminobenzene-sulphonamide in the prevention of measles complications. BMJ. 1:1939;718-720.
115. Gibel H., Litvak A.M. Sulfathiazole in the treatment of measles and its complications. J Paedtr. 21:1942;315-320.
116. Karelitz S., King H., Curtis B., Weschel M. Use of aureomycin and penicillin in the treatment of rubeola in the pre-eruptive and early eruptive phase. Paediatrics. 7:1951;193-199.
117. Hussey G., Simpson J. Nosocomial bacteraemias in measles. Pediatr Infect Dis J. 9:2002;715-717.
118. Fortenberry J.D., Mariscalco M., Louis P.T., Stein F., Jones J.K., Jefferson L.S. Severe laryngotracheobronchitis complicating measles. Am J Dis Child. 146:1992;1040-1043.
119. Weinstein L., Franklin W. The pneumonia of measles. Am J Med Sci. 217:1949;314-324.
120. Usen S., Weber M., Mulholland K., et al. Clinical predictors of hypoxaemia in Gambian children with acute lower respiratory tract infection: prospective cohort study. BMJ. 318:1999;86-91.
121. Duke T., Blaschke A.J., Sialis S., Bonkowsky J.L. Hypoxaemia in acute respiratory and non-respiratory illness in neonates and children in a developing country. Arch Dis Child. 86:2002;108-112.
122. Stiehm E.R., Ashida E., Kim K.S., Winston D.J., Haas A., Gale R.P. Intravenous immunoglobulin as therapeutic agents. Ann Intern Med. 107:1987;367-382.
123. Anon. Appropriate uses of human immunoglobulin in clinical practice: memorandum from the IUS/WHO meeting. Bull World Health Organ1982; 60: 43-47.
124. Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B.V. Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane Review). The Cochrane Library. 2002;Update Software, Oxford. issue 1.
125. Ross L.A., Kim K.S., Mason W.H. Jr, Gomperts E. Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am J Med. 88:1990;313-314.
126. Carmena J., Tomero C., Salcedo M., Pepinan J., Pons E. Pneumonia caused by measles in a pregnant woman with HIV antibodies: response to treatment with immunoglobulins. Enfermedades Infecciosas y Microbiologia Clinica. 14:1996;456-457.
127. Kambarami R.A., Nathoo K.J., Nkrumah F.K., Pirie D.J. Measles epidemic in Harare, Zimbabwe, despite high measles immunization coverage rates. Bull World Health Organ. 69:1991;213-219.
128. Lamb W.H. Epideic measles in a highly immunized rural West African (Gambian) village. Rev Infect Dis. 10:1988;457-462.
129. Samb B., Aaby P., Whittle H., Seck A.M., Simondon F. Decline in measles case fatality ratio after the introduction of measles immunization in rural Senegal. Am J Epidemiol. 145:1997;51-57.
130. Aaby P., Samb B., Simondon F., Coll Seck A.M., Knudsen K., Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ. 311:1995;481-485.
131. Shann F. Non-specific effects of vaccines in developing countries: we need evidence about the effects of vaccines on mortality from all causes. BMJ. 321:2002;1423-1424.
132. Peltola H., Heinonen O.P., Valle M., et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 331:1994;1397-1402.
133. Anon. Progress toward interrupting indigenous measles transmission: region of the Americas, January 1999-September 2000. MMWR2000; 49: 986-90.
134. Elimination of measles in the Republic of South Africa: proposed plan of action W.H.O. 2000. Pretoria. World Health Organization. 1996:1996;1-15.
135. Turnbull F.M., Burgess M.A., McIntyre P.B., et al. The Australian measles control campaign, 1998. Bull World Health Organ. 79:2001;882-888.
136. Salleras L., Dominguez A., Torner N. Confirmed interruption of indigenous measles transmission in Catalonia. Euro Surveill. 6:2001;113-117.
137. Lee M.S., Nokes D.J. Predicting and comparing long-term measles antibody profiles of different immunization policies. Bull World Health Organ. 79:2001;615-624.
138. Slater P.E., Anis E., Leventhal A. Measles control in Israel: a decade of the two-dose policy. Public Health Rev. 27:1999;235-241.
139. Biellik R., Madema S., Taole A., et al. First 5 years of measles elimination in southern Africa: 1996-2000. Lancet. 359:2002;1564-1568.
140. Thomas D.R., King J., Evans M.R., Salmon R.L. Uptake of measles containing vaccines in the measles, mumps, and rubella second-dose catch-up programme in Wales. Commun Dis Public Health. 1:1998;44-47.
141. Anon. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR Recomm Rep1997; 46:1-20.
142. Moss W.J., Cutts F., Griffin D.E. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis. 29:1999;106-112.